Evidence map›Paper›PMID 42042490›Full record

ReviewJournal of imaging2026

A Systematic Review of Deep Learning Approaches for Hepatopancreatic Tumor Segmentation.

Razeen Hussain, Muhammad Mohsin, Dadan Khan, Mohammad Zohaib

Abstract readReview
In one paragraph

Review in Journal of imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Razeen HussainDepartment of Informatics, Bioengineering, Robotics and Systems Engineering, University of Genoa, 16146 Genoa, Italy.ORCID 0000-0002-7579-5069
Muhammad MohsinDepartment of Informatics, Bioengineering, Robotics and Systems Engineering, University of Genoa, 16146 Genoa, Italy.ORCID 0000-0003-1545-2328
Dadan KhanDepartment of Informatics, Bioengineering, Robotics and Systems Engineering, University of Genoa, 16146 Genoa, Italy.ORCID 0000-0002-5412-3650
Mohammad ZohaibDepartment of Informatics, Bioengineering, Robotics and Systems Engineering, University of Genoa, 16146 Genoa, Italy.ORCID 0000-0003-2259-4121

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Deep learning has advanced rapidly in medical image segmentation, yet hepatopancreatic tumor delineation remains challenging due to low contrast, small lesion size, organ variability, and limited high-quality annotations. Existing reviews are outdated or overly broad, leaving recent architectural developments, training strategies, and dataset limitations insufficiently synthesized. To address this gap, we conducted a PRISMA 2020 systematic literature review of studies published between 2021 and 2026 on deep learning-based liver and pancreatic tumor segmentation. From 2307 records, 84 studies met inclusion criteria. U-Net variants continue to dominate, achieving strong liver segmentation but inconsistent tumor accuracy, while transformer-based and hybrid models improve global context modeling at higher computational cost. Attention mechanisms, boundary-refinement modules, and semi-supervised learning offer incremental gains, yet pancreatic tumor segmentation remains notably difficult. Persistent issues, including domain shift, class imbalance, and limited generalization across datasets, underscore the need for more robust architectures, standardized benchmarks, and clinically oriented evaluation. This review consolidates recent progress and highlights key challenges that must be addressed to advance reliable hepatopancreatic tumor segmentation.

Indexed as

CTdeep learninghepatopancreaticliverMRIpancreassegmentationtumor

Identifiers

PMID42042490
PMCPMC13117474

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.